Oxidative stress is a well-known etiologic factor in the development of cardiovascular disease. Oxidation of lipoproteins, and in particular of low density lipoprotein, is a necessary if not obligatory mechanism for the generation of macrophage-derived foam cells, the first major initiating factor in the development of an atherosclerotic plaque. Oxidation of lipoproteins does not result in the generation of a single, defined molecular species, but of a variety of oxidationspecific epitopes, such as oxidized phospholipids and malondialdehyde-lysine epitopes. Unique monoclonal antibodies have been developed to bind these well-defined epitopes, and have been used in in vitro assays to detect them on circulating lipoproteins present in plasma. This article will summarize the accumulating clinical data of one oxidation-specific biomarker, oxidized phospholipids (OxPL) on apoB-100 lipoproteins. Elevated levels of OxPL/apoB predict the presence and progression of coronary, femoral and carotid artery disease, are increased following acute coronary syndromes and percutaneous coronary intervention, and predict the development of death, myocardial infarction, stroke and need for revascularization in unselected populations. OxPL/apoB levels are independent of traditional risk factors and the metabolic syndrome, and enhance the risk prediction of the Framingham Risk Score. The OxPLs measured in this assay reflect the biological activity of the most atherogenic lipoprotein(a) (Lp(a)) particles, reflected in patients with high plasma Lp(a) levels with small apo(a) isoforms. The predictive value of OxPL/ apoB is amplified by Lp(a) and phospholipases such as lipoprotein-associated phospholipase A 2 and secretory phospholipase A 2 , which are targets of therapy in clinical trials. This assay has now been validated in over 10,000 patients and efforts are underway to make it available to the research and clinical communities. 
Oxidation of LDL leads to the generation of a variety of oxidation-specific epitopes (OSE), such as the oxidized phospholipid (OxPL) and malondialdehyde epitopes on LDL. Oxidation of LDL is thought to occur primarily in the vessel wall rather than in plasma, which is strongly enriched in antioxidants. These OSE are biologically active and upregulate adhesion molecules to attract monocytes into the vessel wall, mediate proinflammatory responses in cytokines and upregulatie proinflammatory genes, promote macrophage retention and apoptosis [6, 7] , and are cytotoxic. These OSE are proatherogenic owing to their ability to enhance the unregulated uptake of OxLDL in macrophages through specific pathways generating activated macrophage foam cells ( Figure 1 ). The accumulation of foam cells leads to fatty streak formation. Foam cell necrosis and/or apoptosis and continued accumulation of oxidized lipids in the extracellular space eventually lead to atheroma formation.
Oxidation-specific epitopes are also potent immunogens and lead to activation of T cells and B cells, resulting in the generation of autoantibodies to specific epitopes, which have been described in both humans and animals [8] [9] [10] . In mice, natural antibodies, secreted from OxLDL-specific B-1 cell lines, bind to OSE, block uptake of OxLDL by macrophages, recognize apoptotic cells, and are deposited in atherosclerotic lesions, suggesting a role of the innate immunity system in protecting hosts against these proinflammatory antigens ( Figure 2 ).
Oxidized phospholipids play an important role in atherosclerosis and accumulate in human and mouse lesions. Specific OxPLs have been identified as major regulators of many cell types present in the vessel wall, including endothelial cells, smooth muscle cells, macrophages, dendritic cells and platelets [11, 12] . Furthermore, several receptors and signaling pathways associated with OxPL action have been identified and demonstrated to be upregulated in human lesions [12, 13] . OxPLs mediate plaque destabilization, being present in higher quantities (70-fold) in plaque than plasma [5, 14] . OxPL are key components of OxLDL, apoptotic cells and atherosclerotic lesions, and are important contributors to early events in atherogenesis by activating proinflammatory genes, leading to inflammatory cascades in the vessel wall [11, 12] , which reflect features of chronic inflammatory disease [1, 15] .
We have cloned a series of immuno-dominant IgM antibodies binding to OxLDL from apoE −/− mice [10, 16, 17] . E06 is a well-characterized murine monoclonal antibody that binds to the phosphocholine (PC) head group of oxidized but not native phospholipids [18] . E06 is encoded by non-mutated germline genes and is 100% identical in the variable region of the heavy-chain and κ-light-chains sequences of the T15 natural antibody, which provides the optimal protection to mice against lethal infection with Streptococcus pneumoniae [19] . E06/T15 binds to PC exposed on OxPLs on Cu-OxLDL, as well as OxPL present on apoptotic cells, but also to PC coupled to techoic/lipotechoic acid on the cell wall of bacteria such as S. pneumoniae. Indeed, E06 recognizes OxPL on an equimolar basis when simply present as a PC salt or as PC on OxPL such as 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-PC attached to a variety of different peptides, as well as PC on OxPL covalently linked (via its sn-2 oxidized side chain) to a variety of synthetic peptides irrespective of amino acid sequence [18] . E06 inhibits OxLDL uptake by macrophages, preventing recognition by scavenger receptors, and inhibits a number of other proinflammatory properties of OxPL generated via acute lung injury and infections [20, 21] . E06 also exhibits other important biological functions, such as inhibition of uptake of apoptotic cells by macrophages in vitro [17, 22] , but may promote complement-mediated enhanced clearance of apoptotic cells in vivo, as has been demonstrated for IgM antibodies [23] . Interestingly, pneumococcal vaccination of cholesterol-fed LDLR −/− mice increased the T15/E06 titers and, most strikingly, reduced the progression of atherosclerosis [24, 25] . Overall, these data suggest that PC-based OxPL represents a danger-associated molecular pattern and that effector molecules, such as IgM natural antibodies (e.g., antibody E06/T15), scavenger receptors (e.g., CD36 and SR-B1) and C-reactive protein of the innate immune system evolved to bind and potentially neutralize them [26] .
In the next section we provide a detailed summary of the OxPL/apoB assay in various applications in CVD. Other assays to measure the presence of OSEs on lipoprotein particles exist, and the interested reader is referred to recent articles on this topic that review the advantages and limitations of each assay [27] [28] [29] .
OxPL/apoB methodology
Using E06, we have developed a chemiluminescent ELISA to detect OxPL on human apoB-100 (OxPL/apoB)-containing lipoprotein particles in plasma. This well-validated assay has been previously described in detail [27, 28, 30, 31] . The assay is performed by plating overnight murine monoclonal antibody MB47 (50 μl at 5 μg/ml) [29, 32] , which under the conditions used, captures a saturating amount of apoB-100 on all apoB-containing lipoproteins from plasma. After washing, the plates are coated with 1% bovine serum albumin in tris-(hydroxymethyl) aminomethane-buffered saline. Plasma (50 μl at 1:50 dilution) is added and allowed to incubate for 75 min. This initial step is designed so that each well captures a constant, saturating amount of apoB-100 from plasma and therefore normalizes the OxPL measure to an equal amount of apoB in the well for each patient. Thus, by definition, the OxPL/apoB measurement is independent of apoB and LDL cholesterol levels. Biotinylated E06 (1 μg/ml) is added and allowed to incubate for 1 h. Alkaline phosphatase neutravidin (1:40,000 dilution) is added for 1 h. Lumi-Phos ® 530 (Lumigen, Inc., Southfield, MI, USA; 25 μl) is added for 75 min to detect OxPL per unit of apoB captured (e.g., OxPL in relative light units [RLU]/apoB). Since an equal amount of apoB-100 is captured in each well from each subject, the denominator is the same in all wells (e.g., 1) and, thus, the actual read out is the amount of OxPL as detected by E06. This is detected by chemiluminescent technique and reported in RLU in 100 ms ( Figure 3) . The OxPL/apoB assay is highly specific to the number of OxPL epitopes on individual apoB-100 particles, but does not measure the total amount of OxPL in plasma.
In an early version of this assay prior to 2006, parallel plates were used to document that the wells captured equal amounts of apoB by first capturing apoB with MB47 and then adding the biotinylated murine monoclonal antibody MB24, which detects a separate apoB epitope, to quantitate the amount of captured apoB. The numerator represented OxPL on apoB detected by E06 (in RLU) and the denominator represented the amount of apoB (in RLU) detected on a parallel plate (i.e., E06 in RLU/apoB in RLU = OxPL:apoB ratio, without units). Subsequently, we demonstrated that the correlation between OxPL/apoB RLU vs OxPL/apoB ratio was r = 0.99 in more than 1500 samples [28] . Therefore, this additional step is not performed routinely in current human studies and the data are presented as OxPL/ apoB in RLU, measured as the E06 binding only. In the near future, we will report the values as moles of oxidized PC, as we have generated a standard curve using a small peptide with a known amount of OxPL to equate the amount of OxPL detected by E06 as moles PC. For the data reported thus far, one can compare relative changes or values within assays, but not absolute values among different studies. To minimize variability we have generally performed all the samples in one batch with high and low OxPL standards on each plate. Our coefficient of variability has been 5-10%, which should improve further with the standard curve. 
Relationship of OxPL/apoB & Lp(a): Lp(a) as a preferential carrier of E06-detectable OxPL
Several early clinical studies documented, unexpectedly, that OxPL/apoB correlated strongly with Lp(a) [27, 33] , and not with LDL as expected [31] . Lp(a), which is secreted from the liver, is an independent, causal, genetic risk factor for cardiovascular death and myocardial infarction, and this risk is continuous and linear with increasing Lp(a) levels [34] [35] [36] [37] [38] [39] [40] [41] . A physiological role of Lp(a) and the underlying mechanisms through which it contributes to CVD are still unknown. However, we have shown that Lp(a) preferentially binds OxPL, compared with other lipoproteins [42, 43] , and have proposed that a unique physiological role of Lp(a) may be to bind and transport proinflammatory OxPL in plasma. This would suggest that a sufficient and low level of Lp(a) is beneficial. Indeed, a J-shaped curve relates Lp(a) levels to CVD [44, 45] , suggesting that a small amount of Lp(a) (2-7 mg/ dl) is associated with reduced CVD risk, but that higher levels are associated with increased risk (>25 mg/dl). The OxPL content may also explain this pathophysiological role [31] . When present at high plasma concentrations, Lp(a) would be more atherogenic than native LDL, as it binds with increased affinity to arterial intimal proteoglycans [46] resulting in increased intimal concentration of LDL along with associated proinflammatory OxPL. This hypothesis is now supported by several levels of evidence, including the correlation between OxPL/apoB and Lp(a) in multiple clinical studies [30, 44, 47] ; the presence of OxPL on apo(a) and Lp(a), as detected by a variety of biochemical, immuno-precipitation and ultracentrifugation experiments, which demonstrate that approximately 85% of E06 reactivity (i.e., OxPL) coimmunoprecipitated with Lp(a) [42, 43] ; in vitro transfer studies demonstrating that OxPL from OxLDL are preferentially transferred to Lp(a) rather than LDL in a time-/temperature-dependent fashion [42] ; extraction of purified human Lp(a) with organic solvents followed by liquid chromatogrphy tandem mass spectrometry studies showing that 30-70% of OxPL, both E06-detectable and E06-nondetectable, are extractable; lack of evidence of oxidation of Lp(a) itself (e.g., the lack of malondialdehyde epitopes) [ Oxidized phospholipid/apoB levels were measured in 3481 subjects (1831 black, 1047 white and 603 Hispanic) in the Dallas Heart Study, where it was demonstrated that they were highest in black people followed by white and Hispanic people (p < 0.001 for each comparison) (Figure 4 ). OxPL/apoB levels did not correlate significantly with cardiovascular risk factors, age or gender. However, OxPL/apoB levels strongly correlated with Lp(a) (r = 0.85, p < 0.001), with the correlation showing a 'reverse L' shape when values were log-transformed ( Figure 5 ). In this relationship, there was no correlation between OxPL/apoB and Lp(a) at Lp(a) levels <30 nmol/l (~10 mg/dl), but a very strong correlation above this threshold. Within racial groups, the highest r-values were highest in black individuals, then white and the Hispanic individuals. The OxPL-Lp(a) correlation was highly dependent on underlying apo(a) isoform size, with strong correlations in subjects with small apo(a) isoforms (number of kringle type-IV repeats) that became progressively weaker or absent with larger apo(a) isoforms. Interestingly, there was a negative association between the size of the major apo(a) isoform and OxPL/apoB (r = −0.50, p < 0.001) ( Table  2) , irrespective of racial group. The relationship between OxPL/apoB and Lp(a) remained significant (r = 0.67, p < 0.001) after adjusting for apo(a) isoform size. In summary, this suggests that the OxPL/apoB levels reflect the most atherogenic Lp(a) particles, irrespective of race, and may allow clinical selection of risk profiles above and beyond measuring Lp(a) levels, as recently shown in the European Prospective Investigation of Cancer (EPIC)-Norfolk study [47] . Although basal Lp(a) levels are mainly genetically determined, modest changes above this pre-set baseline do occur in a number of situations, such as in acute phase responses [34] , low fat diet [50,51] and statin therapy [52] . As Lp(a) is a lipoprotein carrier of OxPL, it is likely that the OxPL/apoB levels are also genetically determined to some extent, but in certain situations these values do change from baseline. Studies in twins are underway to examine the strength of the heritability of this relationship.
Relationship of OxPL/apoB & CVD
Association with acute coronary syndromes & percutaneous coronary intervention-Acute coronary syndromes are associated with increased oxidative stress [53] [54] [55] . In two studies, it was demonstrated that acute increases occur in OxPL/apoB in patients following acute coronary syndrome [27] or during uncomplicated percutaneous coronary intervention [33] , suggesting generation and/or release of oxidized lipids into the circulation from atherosclerotic lesions. In a prospective study in patients with acute coronary syndrome [27] , it was demonstrated that OxPL/apoB levels rise rapidly by approximately 54% after an acute myocardial infarction and then tend to decrease toward baseline levels over the next 7 months (Figure 6a ). By contrast, no significant changes were noted in patients with stable coronary artery disease (CAD), patients with normal coronary angiograms and a control group of healthy subjects followed for the same period of time. Further supporting this finding, a follow-up study demonstrated that OxPL/apoB and Lp(a) levels also acutely increased (by 36%; p < 0.0001) ( Figure 6b ) and 64%; p < 0.0001, respectively) immediately following percutaneous coronary intervention and then returned to baseline by 6 h [33] . Immunoprecipitation experiments showed that approximately 50% of OxPLs were present on Lp(a) immediately after percutaneous coronary intervention, whereas the rest were present on non-Lp(a) apoB-100 particles. However, by 6 h more than 90% of OxPL were again present on Lp(a). This supports the role of Lp(a) as a preferential binder and transporter of OxPL [42] .
Association with CAD-It was demonstrated in 504 patients undergoing clinically indicated coronary angiography that elevated levels of OxPL/apoB were strongly and independently correlated with the presence and extent of angiographically documented CAD, defined by >50% diameter stenosis and measured as one-, two-or three-vessel CAD, particularly in patients 60 years of age or younger [48] . In patients <60 years old, the highest quartile of OxPL/apoB was associated with an odds ratio (OR) for CAD of 3.12 (p = 0.004), compared with the lowest quartile. This relationship was markedly accentuated in the setting of hyper-lipidemia (OR: 16.8) (Table 3) . Importantly, in patients <60 years old, OxPL/apoB remained an independent predictor of CAD, even with Lp(a) in the model (Figure 7 ). In the entire cohort, OxPL/apoB levels were independently associated with obstructive CAD for all clinical and lipid measures except for Lp(a), suggesting a common biologic influence on CAD risk. These observations support the hypothesis that although much of the risk attributable to Lp(a) can be explained by its binding of OxPL, additional risk associated with OxPL may be present in younger patients, perhaps through proinflammatory pathways independent of Lp(a). Furthermore, in this specific population selected for clinically indicated coronary angiography, the most atherogenic Lp(a) particles may be better reflected by OxPL/apoB, as suggested by the significantly higher OR for CAD. It is likely that smaller Lp(a) particles have the most OxPL on them, and this leads to some dissociation of OxPL/apoB and Lp(a) levels per se. In fact, in all studies published to date OxPL/apoB was equivalent or superior to risk compared with Lp(a) in risk prediction.
Relationship to peripheral artery disease-In the Bruneck study, a large prospective population-based survey of 40-79-year-old men and women initiated in 1990 where serial plasma levels of OxPL/apoB were measured in 765 and 671 subjects in 1995 and 2000, OxPL/apoB levels predicted the presence of symptomatic CVD and were significantly associated with the presence, extent and development (1995-2000) of carotid and femoral atherosclerosis (Figure 8 ) [28] . The association of OxPL/apoB and Lp(a) was strongest in subjects with small apo(a) isoforms and the highest Lp(a) concentration, suggesting that OxPL/apoB levels may be influenced by the number of K-IV2 repeats (Figure 9 ).
Prediction of cardiovascular events-The
Bruneck study [28, 44] was the first prospective epidemiological study in an unselected population derived from the general community to demonstrate the prognostic utility of OxPL/apoB levels in predicting future death, myocardial infarction, stroke, and transient ischemic attack and revascularization. OxPL/apoB levels predicted the development of cardiovascular events over a 10-year prospective follow-up period. For example, subjects in the highest tertile of OxPL/apoB had a significantly higher risk of cardiovascular events than those in the lowest tertile (hazard ratio: 2.4, 95% CI: 1.3-4.3, p = 0.004) ( Figure 10 ) following multivariable adjustment for traditional risk factors, high-sensitivity C-reactive protein and Lp-PLA 2 activity. These findings were confirmed and extended in the prospective case-controlled EPIC-Norfolk study, consisting of 763 cases and 1397 matched controls composed of 45-79-year-old apparently healthy men and women followed for 6 years [47] . This study showed the highest tertiles of OxPL/apoB were associated with a significantly higher risk of CAD events (OR: 1.67; p < 0.001) compared with the lowest tertiles (Table 4) , after adjusting for age, smoking, diabetes, LDL and high-density lipoprotein cholesterol, and systolic blood pressure.
Furthermore, OxPL/apoB levels provided additional predictive value to the Framingham Risk Score (FRS). By measuring OxPL/apoB in each tertile of FRS, the predicted risk can be either increased or decreased depending on the tertiles of OxPL/apoB. This would allow fine tuning of risk prediction and more accurate assessment of treatment options. For example, in the Bruneck Study, the graded increase in CVD risk across OxPL/apoB tertile groups was evident in the low-, moderate-and high-risk groups as defined by the FRS (Figure 11a ) [44] . This result was validated in the EPIC-Norfolk study ( Figure 11b ) [47] . Finally, OxPL/apoB values are independent of metabolic syndrome parameters [47] .
Receiver-operator characteristic c-index values-To assess the predictive value of the utility of these biomarkers above the FRS, receiver-operator characteristic unconditional c-indexes were generated [47] . The c-index discriminates between individuals at different risk levels and measures the probability that a randomly chosen individual who experienced an event has a higher risk score than a randomly chosen individual who did not experience an event during the same, specific follow-up interval. The c-index is a standard measure of the effect of a new marker in risk prediction and helps to quantify its predictive discrimination, but does have limitations [56] .
The c-index for the FRS was 0.584 (95% CI: 0.558-0.609), a relatively low value that reflects the fact that age and sex were already accounted for as part of the matching design. Adding individual biomarkers to the FRS shows that the c-index increased from 0.584 (95% CI: 0.558-0.609) to 0.618 (95% CI: 0.593-0.642), in progressing order of myeloperoxidase mass, Lp-PLA 2 activity, OxPL/apoB, high-sensitivity C-reactive protein, Lp(a), sPLA 2 mass and sPLA 2 activity. Adding biomarkers to FRS until all biomarkers were present in the model progressively increased the c-index from 0.584 (95% CI: 0.558-0.609) to 0.651 (95% CI: 0.627-0.675) ( Table 5 ).
Relationship of OxPL/apoB to Lp(a), Lp-PLA 2 and sPLA 2 -In prior studies, we have demonstrated that OxPL/apoB reflect the biological activity of small apo(a) isoforms associated with high Lp(a) levels [44, 49] . Furthermore, the OxPL/apoB assay represents OxPL bound by Lp(a) (~85-90%) and non-Lp(a) apoB (10-15%), on average [42] . This relationship is not constant and depends on the underlying LPA genetics, where small isoforms are associated with high OxPL/apoB and high correlations with Lp(a) [49, 57] , but large isoforms are associated with low Lp(a) levels (i.e., <25 mg/dl) and weak-to-absent correlations [49] . To assess whether adding Lp(a) levels to OxPL/apoB enhances the predictive value for CVD events, we performed a 3 × 3 tertile analysis evaluating relationship to CAD events in EPIC-Norfolk. This demonstrated that the relationship of OxPL/apoB and Lp(a) to fatal and nonfatal CAD was accentuated in the highest tertiles of both biomarkers (OR: 1.77, 95% CI: 1.31-2.37), suggesting that they can provide independent and additive information for risk prediction ( Figure 12) [47].
Lipoprotein-associated phospholipase A 2 and sPLA 2 are enzymes that react with OxPLs and cleave the oxidized fatty acid side chain at the sn-2 position of OxPL to generate lysophosphatidylcholine and an oxidized free fatty acid. Both of these biomarkers have been associated with the prediction of cardiovascular events when elevated and are targets of ongoing therapeutic trials to inhibit their activities [50] . Since OxPL and phospholipases may share similar pathophysiology, we evaluated whether the combination of these biomarkers provides enhanced predictive value. In the Bruneck Study, the strength of the association between OxPL/apoB and CVD risk significantly increased with increasing Lp-PLA 2 activity (p = 0.018 for interaction) (Figure 13a) . Similarly, the OR of CAD events associated with the highest tertiles of OxPL/apoB was significantly potentiated (approximately doubled) by the highest tertiles of sPLA 2 activity and mass ( Figure 13b ). In clinical risk prediction, using combinations of these biomarkers may allow stronger predictive value for ascertaining CVD risk. Although these phospholipases are clearly risk predictors, their role as causal risk factors has not been proven yet [58] . In fact, Phase III clinical trials are currently underway to assess whether inhibition of their mass and/or activity will lead to improvement in cardiovascular outcomes [51, 52] .
Change in OxPL/apoB & therapeutic interventions-The OxPL/apoB assay was originally developed as an indicator of minimally oxidized LDL in plasma that might reflect the overall content of circulating OxLDL. We initially postulated that OxPL/apoB levels would increase during hypercholesterolemia and/or atherosclerosis progression and decrease during atherosclerosis regression. Counterintuitively, we have found the opposite, in both animals [59] and humans [33,58,60-65], suggesting that increases in OxPL/apoB in plasma may reflect reduction of the OxPL content of arterial lesions. For example, in New Zealand white rabbits and cynomolgus monkey models of atherosclerosis, which do not have Lp(a) or their Lp(a) does not bind OxPL and/or has E06 immunoreactivity, respectively, OxPL/ apoB levels increased 50-100% in plasma in the setting of lesion regression, concomitant with reduced immunostaining of OxPL in atherosclerotic lesions (Figure 14) [59]. Note that the OxPL staining in the middle panel of Figure 14 has disappeared from the luminal surface, while the OxPL/apoB level goes up in plasma, suggesting a flux of OxPL from the vessel wall to the circulation during dietary induced regression. This suggests that efflux of OxPL occurs preferentially early during atherosclerosis regression from arterial lesions into plasma, even more extensively than depletion of apoB-100 or physical plaque regression. These data suggest that changes in the OxPL/apoB ratio may reflect early atherosclerosis regression. Similarly, in human studies with low fat diets [60, 62] , aged garlic supplementation [58,63] and statin therapy (Table 1) [33,60,61,65], significant increases in OxPL/apoB have been noted shortly after the initiation of the intervention. Although the etiology of these changes is not fully defined, the data are consistent across studies and are associated with treatments considered to be of clinical benefit. For example, in the Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering (MIRACL) trial, an increase in OxPL/apoB and Lp(a) was observed at 16 weeks after initiation of atorvastatin therapy, consistent with a decreased reoccurrence of clinical events, while no such change was observed in the placebo arm. Similarly, an increase in OxPL/apoB, and Lp(a) in response to aged garlic supplements was associated with less progression of coronary artery calcium and improvement in vascular function [58, 63] . Based on the animal data, one may postulate a flux of OxPL from sites of vessel injury or inflammation to the circulation, where they are bound to apoB lipoproteins. In humans, the OxPL preferentially bind to Lp(a), but we have also noted an increase in the Lp(a) levels as well, suggesting that perhaps there is some signaling mechanism leading to increased Lp(a) levels in these settings. These findings are consistent with our suggestion noted above that a 'physiological' role of Lp(a) may be to bind and transport cellular sources of OxPL, such as from apoptotic cells or during normal cellular metabolism where OxPL may be generated. Whether these increases in OxPL/apoB found in the settings of low fat diets, statin therapy, or other potentially beneficial interventions are biomarkers of enhanced efflux from the artery of OxPL, and hence a surrogate of regression, remains to be established.
The apparent paradox is that OxPL/apoB remain strongly independent predictors of CVD in prospective studies, yet here we find they are increased, at least in the short term, in settings of effective therapy. We suggest that a resolution of this paradox may be that with continued therapy, the initial efflux of OxPL from artery into plasma will return to baseline, and the elevated OxPL/apoB will revert to basal levels, or even lower, consistent with reduced risk caused by the intervention. These ideas are currently being tested by extended analyses of adequately powered prospective intervention trials. If confirmed, an early rise in OxPL/apoB might then be used as a useful surrogate biomarker of a beneficial intervention. Such biomarkers are urgently needed.
Conclusion & future perspective
Oxidized phospholipids are strongly implicated in several aspects of CVD. The OxPL/apoB assay provides diagnostic information by strongly reflecting the presence and progression of CVD and prognostic information for predicting future cardiovascular events. It independently complements established risk factors in risk prediction, is independent of the metabolic syndrome and optimizes the predictive value of the FRS. Importantly, from a pathophysiological perspective, OxPL/apoB appears to most closely reflect the biological activity of the most atherogenic Lp(a) particles that are associated with both high Lp(a) levels and small apo(a) isoforms. Since apo(a) isoforms are laborious and expensive to measure, OxPL/apoB levels may accurately reflect the CVD risk of these atherogenic lipoproteins. With Lp(a) now being established as an independent, genetic risk factor for CVD, it may become a target of therapy in future studies. In fact, the antisense oligonucleotide mipomersen and a more specific antisense oligonucleotide targeted to KIV-2 repeats of apo(a) have recently been shown to reduce plasma levels of Lp(a)/apo(a), and their associated OxPL, by 75-86% in Lp(a)-transgenic mice [66, 67] , setting the stage for future clinical development.
Currently, the OxPL/apoB assay is a research tool, but the large clinical database already established suggests that with standardization of the methodology, it will be a useful biomarker that can be used clinically for risk stratification. Future research will focus on the early (and possibly late) changes in OxPL/apoB that occur with therapeutic interventions and whether therapeutic decisions can be guided by assessing these changes in response to the intervention. Finally, since OxPL are implicated in a variety of disorders that have oxidative stress as a key component, such as Alzheimer's disease, multiple sclerosis, nonalcoholic steatohepatitis, rheumatologic disease such as lupus and rheumatoid arthritis, infectious disease and cancer, it would be of interest to assess whether OxPL/apoB and related oxidative biomarkers are associated with and predict noncardiovascular outcomes in patients with these disorders.
induce macrophage apoptosis in a CD36-TLR2-dependent mechanism and link the atherogenicity of OxPL/Lp(a) with a late stage of atherosclerosis that leads to clinical events. 
Executive summary
• Oxidation of lipoproteins, especially low-density lipoprotein (LDL), is a necessary mechanism for foam cell generation as well as initiation and destabilization of atherosclerotic lesions.
• A variety of oxidation-specific epitopes, such as oxidized phospholipids (OxPL) and malondialdehyde-lysine epitopes, are generated during oxidation.
• EO6 is a murine monoclonal antibody that binds to the phosphocholine head group of oxidized but not native phospholipids.
• The OxPL/apoB-lipoprotein(a) (Lp(a)) correlation is highly dependent on apo(a) isoform size, with strong correlations with small apo(a) isoforms and weak or absent with larger apo(a) isoforms.
• OxPL/apoB levels correlate with Lp(a) and not with LDL, which could propose a unique physiological role of Lp(a) to bind and transport pro-inflammatory OxPL in plasma. OxPL/apoB reflects the most atherogenic Lp(a) particles associated with small isoforms and high Lp(a) levels.
Relationship of OxPL/apoB & cardiovascular disease
• OxPL/apoB increases acutely in patients following acute coronary syndromes or during uncomplicated percutaneous coronary intervention.
• OxPL/apoB levels are independently correlated with the presence and extent of angiographically documented coronary artery disease and the presence and progression of carotid and femoral atherosclerosis.
• Elevated baseline levels of OxPL/apoB independently predict the development of cardiovascular events over a 10-year prospective follow-up in a population derived from general community and provide additional predictive value to the Framingham Risk Score, are independent of the metabolic syndrome and increase the c-index for predicting events in a model with Framingham Risk Score, traditional risk factors, and other oxidative and inflammatory biomarkers, including high-sensitivity C-reactive protein.
• The strength of the association between OxPL/apoB and cardiovascular disease risk significantly increases with increasing Lp-PLA 2 activity, secretory phospholipase A 2 activity and mass.
• In both animals and humans, efflux of OxPL from arterial lesions into plasma was observed to occur preferentially early during atherosclerosis regression (low fat diets, statin therapy and aged garlic supplements).
Conclusion
• OxPL/apoB levels provide diagnostic and prognostic information in strongly reflecting the presence and progression of cardiovascular disease and predicting future cardiovascular events, and may be a useful assay in research and clinical applications. Spearman correlation (r-values) between lipoprotein(a) and oxidized phospholipid/apoB by race and sex. Table 3 Odds ratios for obstructive coronary artery disease according to quartiles of the ratio of oxidized phospholipids to apoB-100 and levels of lipoprotein(a) in patients with and without hypercholesterolemia.
Patient group Oxidized phospholipid:apoB-100 ratio

No hypercholesterolemia Hypercholesterolemia
Number with CAD (%) OR (95% CI) Number with CAD (%) OR (95% CI) 
All patients
Table 4
Odds ratio (95% CI) of coronary artery disease by tertiles of oxidized phospolipid/apoB. Statistical values for area under receiver operating characteristic curves. 
